Apoa5 (ab) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50–70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor- agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Recently, it was demonstrated that ApoA5 is present in human serum detected by polyclonal antibodies against both the NH2 and COOH termini, although at much lower concentration than other apolipoproteins.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Target: Apoa5 (ab) Immunogen: Purified recombinant fragment of human APOA5 (AA: 20-363) expressed in E. coli. |
| Host | Mouse |
| Reactivity | Human |
| Assay Type | Concentration: 1 mg/ml |
| Recommended Dilution | ELISA: 1/10000, WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG1 |
| Observed MW | 41 kDa |
| Purification | Purified from ascites by Protein G chromatography. |
| Size 1 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | PBS, containing 0.03% sodium azide. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q6Q788 |
| Gene ID | 116519 |
| OMIM | 144650 |
| Background | Antibody anti-ab |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Descripción
Related Products
Apoa5 (ab) Antibody
Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50–70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor- agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Recently, it was demonstrated that ApoA5 is present in human serum detected by polyclonal antibodies against both the NH2 and COOH termini, although at much lower concentration than other apolipoproteins.
Ver Producto